Reports for APOTEX INC
Company Name APOTEX INC |
||
|---|---|---|
Totals |
||
Shortage reports |
3367 |
|
| Actual shortage: | 219 (7%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3138 (93%) | |
Discontinuation Reports |
365 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 341 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
68 (28%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-ESOMEPRAZOLE | 40MG | TABLET (DELAYED-RELEASE) | Resolved | 2023-03-30 | 2023-08-23 | 188427 |
| APO-ESOMEPRAZOLE | 20MG | TABLET (DELAYED-RELEASE) | Resolved | 2023-06-09 | 2023-07-27 | 194568 |
| APO-EXEMESTANE | 25MG | TABLET | Resolved | 2017-03-10 | 2019-06-12 | 314 |
| APO-EZETIMIBE | 10MG | TABLET | Resolved | 2017-03-10 | 2017-03-15 | 318 |
| APO-EZETIMIBE | 10MG | TABLET | Resolved | 2017-03-11 | 2017-04-25 | 655 |
| APO-EZETIMIBE | 10MG | TABLET | Resolved | 2017-04-04 | 2017-04-25 | 5366 |
| APO-EZETIMIBE | 10MG | TABLET | Resolved | 2017-05-04 | 2017-07-18 | 8862 |
| APO-EZETIMIBE | 10MG | TABLET | Resolved | 2017-05-16 | 2017-07-18 | 10400 |
| APO-EZETIMIBE | 10MG | TABLET | Resolved | 2019-08-14 | 2019-10-07 | 91535 |
| APO-EZETIMIBE | 10MG | TABLET | Resolved | 2018-02-01 | 2018-04-23 | 37956 |
| APO-EZETIMIBE | 10MG | TABLET | Actual shortage | 2023-12-08 | 2024-01-19 | 212961 |
| APO-EZETIMIBE | 10MG | TABLET | Actual shortage | 2024-01-05 | 2024-01-19 | 215247 |
| APO-FAMCICLOVIR | 500MG | TABLET | Resolved | 2023-12-08 | 2024-01-19 | 212955 |
| APO-FAMCICLOVIR | 250MG | TABLET | Resolved | 2017-09-26 | 2018-01-18 | 23553 |
| APO-FAMCICLOVIR | 125MG | TABLET | Resolved | 2017-10-23 | 2018-01-19 | 26572 |
| APO-FAMCICLOVIR | 500MG | TABLET | Resolved | 2017-03-12 | 2017-04-17 | 719 |
| APO-FAMCICLOVIR | 500MG | TABLET | Resolved | 2020-08-12 | 2020-12-29 | 122062 |
| APO-FAMCICLOVIR | 250MG | TABLET | Resolved | 2020-08-19 | 2021-01-11 | 122480 |
| APO-FAMCICLOVIR | 125MG | TABLET | Resolved | 2020-10-07 | 2020-12-29 | 125803 |
| APO-FAMCICLOVIR | 250MG | TABLET | Resolved | 2020-02-05 | 2020-02-25 | 105333 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-FENTANYL MATRIX | 100MCG | PATCH | Discontinued | 2018-02-23 | 2018-12-28 | 40741 |
| APO-FENTANYL MATRIX | 25MCG | PATCH | Discontinued | 2018-09-07 | 2018-09-15 | 60489 |
| APO-FENTANYL MATRIX | Discontinued | 2018-09-07 | 2018-09-15 | 60494 | ||
| APO-FENTANYL MATRIX | 75MCG | PATCH | Discontinued | 2018-09-07 | 2018-09-15 | 60497 |
| APO-FLUNISOLIDE NASAL SPRAY | 0.25MG | METERED-DOSE PUMP | Discontinued | 2018-02-26 | 2018-02-26 | 40965 |
| APO-FLUVOXAMINE TABLETS | 100MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4713 |
| APO-FLUVOXAMINE TABLETS | 50MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4716 |
| APO-GAIN LIQ 20MG/ML | 20MG | SOLUTION | Discontinued | 2019-01-02 | 2019-01-02 | 70815 |
| APO-GAIN LIQ 20MG/ML | 20MG | SOLUTION | Discontinued | 2018-02-26 | 2018-02-26 | 40997 |
| APO-GEMFIBROZIL | 600MG | TABLET | Discontinued | 2017-03-31 | 2017-03-31 | 4927 |
| APO-GEMFIBROZIL CAP 300MG USP | 300MG | CAPSULE | Discontinued | 2017-03-31 | 2018-12-07 | 4920 |
| APO-GEMFIBROZIL CAP 300MG USP | Discontinued | 2019-06-12 | 2019-06-12 | 86557 | ||
| APO-GLICLAZIDE | 80MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60512 |
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94452 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94446 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94449 | ||
| APO-HALOPERIDOL TAB 2MG | 2MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1084 |
| APO-HALOPERIDOL TAB 5MG | 5MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1087 |
| APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
| APO-HYDROMORPHONE CR | 12MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110962 |